PMP22 and Charcot-Marie-Tooth disease type 1A: For direct targeting of PMP22, Zhao et al., recently showed that direct downregulation of PMP22 via antisense oligonucleotide (ASO) can ameliorate the clinical symptoms associated with peripheral neuropathy in animal models of CMT1A.